David N. Louis

ORCID: 0000-0002-9423-4099
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Brain Metastases and Treatment
  • Neurofibromatosis and Schwannoma Cases
  • Cancer-related molecular mechanisms research
  • Neuroblastoma Research and Treatments
  • Meningioma and schwannoma management
  • MicroRNA in disease regulation
  • Chromatin Remodeling and Cancer
  • Cancer-related Molecular Pathways
  • Radiomics and Machine Learning in Medical Imaging
  • Epigenetics and DNA Methylation
  • Genetic factors in colorectal cancer
  • Hedgehog Signaling Pathway Studies
  • Microtubule and mitosis dynamics
  • RNA modifications and cancer
  • Sarcoma Diagnosis and Treatment
  • Cancer, Hypoxia, and Metabolism
  • Lung Cancer Treatments and Mutations
  • Bone Tumor Diagnosis and Treatments
  • Ocular Oncology and Treatments
  • Genomics and Chromatin Dynamics
  • Animal Genetics and Reproduction
  • Single-cell and spatial transcriptomics
  • RNA Research and Splicing

Massachusetts General Hospital
2015-2024

Harvard University
2015-2024

Brigham and Women's Hospital
1999-2024

Center for Cancer Research
2012-2024

Mass General Brigham
2023-2024

Université Grenoble Alpes
2021

CEA LETI
2021

Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2021

Brown University
2021

Lifespan
2021

Most patients with non–small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets epidermal growth factor receptor (EGFR). However, about 10 percent of a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity gefitinib are unknown.

10.1056/nejmoa040938 article EN New England Journal of Medicine 2004-05-19

Human cancers are complex ecosystems composed of cells with distinct phenotypes, genotypes, and epigenetic states, but current models do not adequately reflect tumor composition in patients. We used single-cell RNA sequencing (RNA-seq) to profile 430 from five primary glioblastomas, which we found be inherently variable their expression diverse transcriptional programs related oncogenic signaling, proliferation, complement/immune response, hypoxia. also observed a continuum stemness-related...

10.1126/science.1254257 article EN Science 2014-06-13

Gliomas are common malignant neoplasms of the central nervous system. Among major subtypes gliomas, oligodendrogliomas distinguished by their remarkable sensitivity to chemotherapy, with approximately two thirds anaplastic (malignant) responding dramatically combination treatment procarbazine, lomustine, and vincristine (termed PCV). Unfortunately, no clinical or pathologic feature these tumors allows accurate prediction response chemotherapy. Anaplastic also a unique constellation molecular...

10.1093/jnci/90.19.1473 article EN JNCI Journal of the National Cancer Institute 1998-10-07

Normal human cells exhibit a limited replicative life span in culture, eventually arresting growth by process termed senescence. Progressive telomere shortening appears to trigger senescence normal fibroblasts and retinal pigment epithelial cells, as ectopic expression of the telomerase catalytic subunit, hTERT, immortalizes these cell types directly. Telomerase alone is insufficient enable certain other evade senescence, however. Such including keratinocytes mammary appear require loss...

10.1128/mcb.20.4.1436-1447.2000 article EN Molecular and Cellular Biology 2000-02-01

Abstract Brain metastases are associated with a dismal prognosis. Whether brain harbor distinct genetic alterations beyond those observed in primary tumors is unknown. We performed whole-exome sequencing of 86 matched metastases, tumors, and normal tissue. In all clonally related cancer samples, we branched evolution, where metastatic sites shared common ancestor yet continued to evolve independently. 53% cases, found potentially clinically informative the not detected primary-tumor sample....

10.1158/2159-8290.cd-15-0369 article EN Cancer Discovery 2015-09-27

Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well composition tumor microenvironment (TME). We dissected these influences in isocitrate dehydrogenase (IDH)-mutant gliomas by combining 14,226 single-cell RNA sequencing (RNA-seq) profiles from 16 patient samples with bulk RNA-seq 165 samples. Differences between IDH-mutant astrocytoma oligodendroglioma can be primarily explained distinct TME signature genetic events, whereas both types share similar...

10.1126/science.aai8478 article EN cc-by Science 2017-03-30
Coming Soon ...